<DOC>
	<DOCNO>NCT00186108</DOCNO>
	<brief_summary>The primary purpose study evaluate ability oral triamcinalone give twice day patient androgen independent prostate cancer produce sustain biochemical response . Secondary goal describe safety tolerability dose schedule , determine time sustain biochemical response , determine duration biochemical response , determine time disease progression .</brief_summary>
	<brief_title>A Pilot Study Evaluating Oral Triamcinalone Patients With Androgen Independent Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>18 year age old Histologically document adenocarcinoma prostate Currently receive LHRH agonist castrate level testosterone orchiectomy Must rise PSA despite anti androgen withdrawal Exhibit 2 consecutive rise PSA last hormonal manipulation Minimum PSA great 5 KPS great 80 % Normal cortisol level entry Life expectancy great 6 month Provide write consent pursuant regulatory requirement prior initiation study procedure Exclusion criterion : Younger 18 year Patients without prostate cancer</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>Oral Triamcinalone</keyword>
	<keyword>Prostate Cancer</keyword>
</DOC>